POP Biotechnologies, Inc. (POP BIO) is a preclinical stage biopharmaceutical company developing innovative nanomedical solutions to critical medical challenges. POP BIO, founded in 2015 by Jonathan Lovell, Ph.D., Jonathan Smyth, JD, and Kevin Carter, to realize the potential of the revolutionary porphyrin-phospholipid (POP) liposome technology developed by Dr. Lovell through over $3M in NIH funding. POP BIO generated initial capital through awards and investments from Revolution LLC (Washington D.C.), z80 Labs (Buffalo, NY), and SUNY Buffalo.

POP BIO’s oncology lead, NP-01, is a light-activated cancer therapy incorporating the oncolytic drug doxorubicin in a unique photosensitive carrier that provides targeted and enhanced release of drug to tumors upon laser light exposure. NP-01 is designed to address solid tumors which lack effective treatment options, such as cutaneous metastatic breast cancer (CMBC), liver cancer, and pancreatic cancer, by combining the potency of a widely-uti...
POP Biotechnologies, Inc. (POP BIO) is a preclinical stage biopharmaceutical company developing innovative nanomedical solutions to critical medical challenges. POP BIO, founded in 2015 by Jonathan Lovell, Ph.D., Jonathan Smyth, JD, and Kevin Carter, to realize the potential of the revolutionary porphyrin-phospholipid (POP) liposome technology developed by Dr. Lovell through over $3M in NIH funding. POP BIO generated initial capital through awards and investments from Revolution LLC (Washington D.C.), z80 Labs (Buffalo, NY), and SUNY Buffalo.

POP BIO’s oncology lead, NP-01, is a light-activated cancer therapy incorporating the oncolytic drug doxorubicin in a unique photosensitive carrier that provides targeted and enhanced release of drug to tumors upon laser light exposure. NP-01 is designed to address solid tumors which lack effective treatment options, such as cutaneous metastatic breast cancer (CMBC), liver cancer, and pancreatic cancer, by combining the potency of a widely-utilized chemotherapy with photodynamically enhanced and localized release. Described by NIH Director Dr. Francis Collins as “a terrific example of how bioengineering can bring fresh solutions to longstanding medical challenges,” NP-01 provides a two-fold benefit upon light activation: 1) generation of reactive oxygen species which permeabilize irradiated tumors, significantly improving drug extravasation, and reducing tumor blood flow; and 2) localized release of doxorubicin, penetrating difficult tumor tissues while minimizing adverse effects associated with systemic exposure.

POP BIO’s Spontaneous Nanoparticle Antigen-attachment Particle-formation (SNAP) platform is a unique liposome-based system for creating highly immunogenic vaccines and immunotherapies. SNAP liposomes have a unique binding mechanism, enabling the efficient, rapid, and stable binding of one or more vaccine antigens to nanoparticles, forming vaccines with a markedly greater immune response compared to existing adjuvants. SNAP allows for mixing of antigens immediately before administration, providing a stockpileable solution for emerging diseases, bioterrorism, pandemics, or personalized medicines, while generating orders of magnitude higher antibody responses due to stable, high-density antigen presentation to a patient's immune system. POP BIO, working with industry and institutional development partners, actively seeks to create and evaluate SNAP-enabled vaccines and immunotherapies.
More information